Silence Therapeutics (SLN) Stock Price, News & Analysis

Company Overview

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism. Both programs have advanced through early clinical stages, generating proof-of-concept data. Silence also maintains a portfolio of preclinical research programs targeting liver-related diseases, while exploring strategic collaborations to broaden the reach of its RNAi platform across multiple therapeutic areas.

Founded in the United Kingdom and headquartered in London, Silence Therapeutics operates research and development facilities in Europe and the United States. The company has navigated the evolving RNA therapeutics landscape since the early 2000s, transitioning from discovery research into clinical development. Under the leadership of Chief Executive Officer Eric M. Rose, Silence continues to advance its pipeline with the objective of delivering novel RNAi medicines to patients with high-unmet medical needs worldwide.

Key Stats

• Today's Range: $4.50 to $5.00
• 50-Day Range: $4.51 to $6.49
• 52-Week Range: $1.97 to $20.48
• Volume: 116,674 shs
• Average Volume: 47,879 shs
• Market Capitalization: $134.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.60
• Consensus Rating: Moderate Buy

Silence Therapeutics Stock Analysis - MarketRank™

Silence Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 551st out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Silence Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Silence Therapeutics has a consensus price target of $32.60, representing about 622.8% upside from its current price of $4.51.

Amount of Analyst Coverage

Silence Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Silence Therapeutics are expected to grow in the coming year, from ($1.77) to ($1.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Silence Therapeutics is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Silence Therapeutics is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Silence Therapeutics has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.55% of the outstanding shares of Silence Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Silence Therapeutics has a short interest ratio ("days to cover") of 9.4.

Change versus previous month

Short interest in Silence Therapeutics has recently decreased by 1.12%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Silence Therapeutics does not currently pay a dividend.

Dividend Growth

Silence Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.55% of the outstanding shares of Silence Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Silence Therapeutics has a short interest ratio ("days to cover") of 9.4.

Change versus previous month

Short interest in Silence Therapeutics has recently decreased by 1.12%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.65

News Sentiment

Silence Therapeutics has a news sentiment score of 1.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Silence Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Silence Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.10% of the stock of Silence Therapeutics is held by insiders.

Percentage Held by Institutions

98.73% of the stock of Silence Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SLN Stock Analysis - Frequently Asked Questions

How have SLN shares performed this year?

Silence Therapeutics' stock was trading at $6.88 at the beginning of 2025. Since then, SLN shares have decreased by 34.4% and is now trading at $4.51.

How were Silence Therapeutics' earnings last quarter?

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) issued its quarterly earnings results on Thursday, August, 7th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.27) by $0.27. The business had revenue of $0.22 million for the quarter, compared to analysts' expectations of $8.50 million. Silence Therapeutics had a negative trailing twelve-month return on equity of 67.48% and a negative net margin of 294.20%.

Who are Silence Therapeutics' major shareholders?

Top institutional investors of Silence Therapeutics include Redmile Group LLC (7.23%), Frazier Life Sciences Management L.P., Boothbay Fund Management LLC and Marshall Wace LLP.

How do I buy shares of Silence Therapeutics?

Shares of SLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Silence Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Silence Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Novo Nordisk A/S (NVO).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/13/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SLN
• CIK: 1479615
• Web: www.silence-therapeutics.com
• Phone: 44-0-20-3457-6900
• Fax: N/A
• Employees: 100
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Silence Therapeutics: $32.60
• High Price Target: $75.00
• Low Price Target: $3.00
• Potential Upside/Downside: +622.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.31 million
• Net Margins: -294.20%
• Pretax Margin: -291.12%
• Return on Equity: -67.48%
• Return on Assets: -40.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.06
• Quick Ratio: 10.06

Sales & Book Value

• Annual Sales: $27.17 million
• Price / Sales: 4.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.48 per share
• Price / Book: 1.01

Miscellaneous

• Outstanding Shares: 29,930,000
• Free Float: N/A
• Market Cap: $134.98 million
• Optionable: Not Optionable
• Beta: 1.38